Possibly Nepal's first immunotherapy study in an indexed journal, from our team. Low-dose immunotherapy shows real-world outcomes at a fraction of standard cost. Cancer care that fits Nepal's reality. #Nepal #Immunotherapy #Oncology #CancerResearch #क्यान्सर
Can low-dose immunotherapy work when standard doses are unaffordable?
At @KtmCancerCenter, we studied low-dose nivolumab (20–40 mg), finding encouraging real-world outcomes with manageable toxicity.
Possibly Nepal’s first indexed-journal study on immunotherapy.
#CancerResearchView quoted post on X
